Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Portfolio Pulse from
Theratechnologies presented data at CROI highlighting the limitations of using BMI alone to assess cardiovascular risk in people with HIV. The study suggests incorporating screening for excess visceral abdominal fat for better risk identification.
March 12, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theratechnologies presented findings at CROI that BMI alone is insufficient for assessing cardiovascular risk in HIV patients, advocating for EVAF screening.
The presentation at CROI by Theratechnologies could enhance the company's reputation in the HIV treatment space, potentially leading to increased interest in their products and services. This could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80